NCT07579260Not yet recruiting
IMPACT-HTN Study of Patients With Hypertension
Prospective Early Patient Experience Initiative (IMPACT-HTN)
Source: ClinicalTrials.gov · Last updated 29 Jun 2026
Brief summary (registry, in English)
An estimated 120 million people have high blood pressure (hypertension) in the US, of which approximately 10% have resistant hypertension. This study aims to enroll patients who continue to have hypertension while being treated with at least two medications. The study will follow patients for approximately 3 months and collect real-world information on changes in their health to identify an ideal patient profile that would benefit from 4th-line antihypertensive therapies, including, but not limited to, FDA-approved aprocitentan, renal denervation, mineralocorticoid receptor antagonists, etc.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 6 May 2026
- Start date
- 1 Jul 2026
- Primary completion date
- 1 Apr 2027
- Lead sponsor
- Vivek Bhalla
- Diseases
- High blood pressure
- NCT number
- NCT07579260
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Jul 2026 to the primary completion date, 1 Apr 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Confirmed severe hypertension (grade 3) defined as SiSBP greater than or equal to 180 mmHg and/or Sitting Diastolic Blood Pressure (SiDBP) greater than or equal to 110 mmHg
- Clinically significant unstable cardiac disease at screening or in the past in the opinion of the investigator
- Heart failure NYHA functional class III and IV or NT-proBNP \> 500 pg/mL
Lab values
- Severe renal insufficiency or eGFR \< 15 mL/min/1.73m2
- Moderate to severe hepatic impairment (Child-Pugh B and C) or elevated aminotransferase (\> 3 x ULN)
Who the study is looking for
- Signed and dated informed consent form
- Ability to answer survey questions and to report blood pressure reading monthly
- Male and female participants; 18 years or older
- Treated with at least 2 antihypertensive therapies of different pharmacological classes for at least 4 weeks before the screening visit
- Mean Sitting Systolic Blood Pressure (SiSBP) greater or equal to 130 mmHg
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Duke University Hospital Coordinator of this site? Confirm its status | Durham | United States | Unknown status |
| Stanford University Hypertension Center Coordinator of this site? Confirm its status | Palo Alto | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.